New cancer clinical trial: Double Immune Checkpoint Inhibitors in PD-L1-positive Stage IV Non-small Lung CancEr

Published on: March 19, 2018 at 12:00PM
Condition:   Non-Small Cell Lung Cancer Metastatic
Interventions:   Drug: Ipilimumab;   Drug: Nivolumab
Sponsor:   Intergroupe Francophone de Cancerologie Thoracique
Not yet recruiting
http://ift.tt/2IEtezQ